OncoMatch/Clinical Trials/NCT07767630

Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma

Is NCT07767630 recruiting? Yes, currently enrolling (Sep 2026). This Early Phase 1 trial studies [211At]MABG for neuroblastoma (nb).

Early Phase 1RecruitingSichuan UniversityNCT07767630Data as of Sep 2026Location: China

Treatment: [211At]MABG — Fractionated dosing of \[211At\]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma

Extracted eligibility criteria

Treatments studied

Other

[211At]MABG

Cancer type

Neuroblastoma

Biomarker criteria

Required: SLC6A2 mibg avidity

Patients diagnosed with MIBG avid lesions

Required: SLC6A2 mibg avidity

All measurable soft tissue lesions must be MIBG-avid

Demographics

Ages 1–100

Lab requirements

Blood counts

Kidney function

Liver function

Adequate organ function and hematologic parameters

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Is NCT07767630 currently recruiting?

Yes, this trial is currently recruiting patients.

Does this trial require SLC6A2?

Yes, SLC6A2 mibg avidity is a required biomarker for enrollment.

Does this trial require SLC6A2?

Yes, SLC6A2 mibg avidity is a required biomarker for enrollment.

Is there an age limit?

Yes. Patients must be 100 years or younger and at least 1 years old.

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.